Poseida Therapeutics (NASDAQ:PSTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report released on Wednesday, Benzinga reports. The firm currently has a $20.00 price target on the stock.

Poseida Therapeutics Stock Performance

NASDAQ PSTX opened at $2.47 on Wednesday. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. Poseida Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.27. The company has a market capitalization of $239.92 million, a PE ratio of -2.08 and a beta of 0.51. The company has a fifty day moving average of $2.76 and a two-hundred day moving average of $2.85.

Poseida Therapeutics (NASDAQ:PSTX) last announced its earnings results on Monday, August 5th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. The business had revenue of $25.97 million during the quarter, compared to analysts’ expectations of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. As a group, analysts expect that Poseida Therapeutics will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Poseida Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Poseida Therapeutics by 89.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after buying an additional 391,801 shares during the period. Renaissance Technologies LLC grew its holdings in Poseida Therapeutics by 53.4% in the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after buying an additional 297,500 shares during the period. Blair William & Co. IL grew its holdings in Poseida Therapeutics by 41.3% in the 1st quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after buying an additional 282,310 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Poseida Therapeutics during the second quarter worth about $241,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.